Literature DB >> 35449450

Effects of a psychedelic 5-HT2A receptor agonist on anxiety-related behavior and fear processing in mice.

Carine Bécamel1, Dimitri De Bundel2, Błażej D Pędzich3, Sarah Rubens3, Mehdi Sekssaoui1, Anouk Pierre3, Andries Van Schuerbeek3, Philippe Marin1, Joel Bockaert1, Emmanuel Valjent1.   

Abstract

Psychedelic-assisted psychotherapy gained considerable interest as a novel treatment strategy for fear-related mental disorders but the underlying mechanism remains poorly understood. The serotonin 2A (5-HT2A) receptor is a key target underlying the effects of psychedelics on emotional arousal but its role in fear processing remains controversial. Using the psychedelic 5-HT2A/5-HT2C receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) and 5-HT2A receptor knockout (KO) mice we investigated the effect of 5-HT2A receptor activation on emotional processing. We show that DOI administration did not impair performance in a spontaneous alternation task but reduced anxiety-like avoidance behavior in the elevated plus maze and elevated zero maze tasks. Moreover, we found that DOI did not block memory recall but diminished fear expression in a passive avoidance task. Likewise, DOI administration reduced fear expression in an auditory fear conditioning paradigm, while it did not affect retention of fear extinction when administered prior to extinction learning. The effect of DOI on fear expression was abolished in 5-HT2A receptor KO mice. Administration of DOI induced a significant increase of c-Fos expression in specific amygdalar nuclei. Moreover, local infusion of the 5-HT2A receptor antagonist M100907 into the amygdala reversed the effect of systemic administration of DOI on fear expression while local administration of DOI into the amygdala was sufficient to suppress fear expression. Our data demonstrate that activation of 5-HT2A receptors in the amygdala suppresses fear expression but provide no evidence for an effect on retention of fear extinction.
© 2022. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35449450      PMCID: PMC9117291          DOI: 10.1038/s41386-022-01324-2

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   8.294


  90 in total

Review 1.  The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis.

Authors:  Simon B Goldberg; Brian T Pace; Christopher R Nicholas; Charles L Raison; Paul R Hutson
Journal:  Psychiatry Res       Date:  2020-01-02       Impact factor: 3.222

2.  5-HT1A-receptor agonist modified amygdala activity and amygdala-associated social behavior in a valproate-induced rat autism model.

Authors:  Chao-Chuan Wang; Hui-Ching Lin; Yun-Han Chan; Po-Wu Gean; Yen Kung Yang; Po See Chen
Journal:  Int J Neuropsychopharmacol       Date:  2013-07-03       Impact factor: 5.176

Review 3.  Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders.

Authors:  N Singewald; C Schmuckermair; N Whittle; A Holmes; K J Ressler
Journal:  Pharmacol Ther       Date:  2014-12-27       Impact factor: 12.310

4.  Impaired hippocampal-dependent learning and functional abnormalities in the hippocampus in mice lacking serotonin(1A) receptors.

Authors:  Z Sarnyai; E L Sibille; C Pavlides; R J Fenster; B S McEwen; M Toth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

5.  Pharmacological profile of novel psychoactive benzofurans.

Authors:  Anna Rickli; Simone Kopf; Marius C Hoener; Matthias E Liechti
Journal:  Br J Pharmacol       Date:  2015-04-24       Impact factor: 8.739

6.  6 Hz corneal kindling in mice triggers neurobehavioral comorbidities accompanied by relevant changes in c-Fos immunoreactivity throughout the brain.

Authors:  Giulia Albertini; Laura Walrave; Thomas Demuyser; Ann Massie; Dimitri De Bundel; Ilse Smolders
Journal:  Epilepsia       Date:  2017-11-20       Impact factor: 5.864

7.  MDMA-induced impairment in primates: antagonism by a selective norepinephrine or serotonin, but not by a dopamine/norepinephrine transport inhibitor.

Authors:  Christopher D Verrico; Laurie Lynch; Michele A Fahey; Ashley-Kay Fryer; Gregory M Miller; Bertha K Madras
Journal:  J Psychopharmacol       Date:  2008-02-28       Impact factor: 4.153

8.  Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.

Authors:  Roland R Griffiths; Matthew W Johnson; Michael A Carducci; Annie Umbricht; William A Richards; Brian D Richards; Mary P Cosimano; Margaret A Klinedinst
Journal:  J Psychopharmacol       Date:  2016-12       Impact factor: 4.153

9.  5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice.

Authors:  Adam L Halberstadt; Iris van der Heijden; Michael A Ruderman; Victoria B Risbrough; Jay A Gingrich; Mark A Geyer; Susan B Powell
Journal:  Neuropsychopharmacology       Date:  2009-03-25       Impact factor: 7.853

10.  Cognitive dysfunction, elevated anxiety, and reduced cocaine response in circadian clock-deficient cryptochrome knockout mice.

Authors:  Dimitri De Bundel; Giuseppe Gangarossa; Anne Biever; Xavier Bonnefont; Emmanuel Valjent
Journal:  Front Behav Neurosci       Date:  2013-10-24       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.